Sam Altman, CEO of OpenAI, is increasing his investment in Retro Biosciences, a San Francisco biotech startup aiming to extend the healthy human lifespan by ten years. After initially funding the startup's $180 million seed round, he is now participating in a $1 billion Series A round. The startup, which has developed methods to convert regular cells into stem cells with OpenAI's help, plans to create drugs targeting diseases such as Alzheimer's. This move reflects a growing trend of billionaire interest in longevity-focused biotech ventures.
Altman is investing $1 billion in Retro Biosciences, a biotech startup focused on extending healthy human lifespan by targeting diseases like Alzheimer's.
Retro Biosciences plans to launch trials for drugs that could potentially add 10 years to human lifespan, marking a significant move in longevity research.
Collection
[
|
...
]